Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 121
- Registration Number
- NCT05169515
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Sourasky Medical Center, Tel-Aviv, Israel
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 71
- Registration Number
- NCT05170204
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Aichi, Japan
🇯🇵Sendai Kousei Hospital, Miyagi, Japan
🇺🇸University of South Alabama, Mobile, Alabama, United States
A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT05164133
- Locations
- 🇿🇦
Global Clinical Trials Sunnyside, Pretoria, South Africa
🇪🇸Hospital Sant Joan de Deu - PIN; Unitat de Recerca - Farmacia, Esplugues de Llobregat, Barcelona, Spain
🇪🇸Hospital Infantil Universitario Niño Jesus; Sección de Neuropediatria, Madrid, Spain
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT05155345
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇲🇩ICS ARENSIA Exploratory Medicine, Chisinau, Moldova, Republic of
🇵🇱Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland
A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 394
- Registration Number
- NCT05151731
- Locations
- 🇦🇷
Centro de ojos Loria, Lomas de Zamora, Argentina
🇦🇷Oftar, Mendoza, Argentina
🇦🇷Microcirugía Ocular S.A, Rosario, Argentina
A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 187
- Registration Number
- NCT05151744
- Locations
- 🇨🇦
Retina Institute of Ottawa, Ottawa, Ontario, Canada
🇺🇸Win Retina, Arcadia, California, United States
🇺🇸Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT05129280
- Locations
- 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT05126966
- Locations
- 🇭🇰
Hong Kong Eye Hospital; CUHK Eye Centre, Mongkok, Hong Kong
🇵🇹Hospital de Sao Joao; Servico de Oftalmologia, Porto, Portugal
🇩🇰Sjællands Universitetshospital, Roskilde; Øjenafdelingen, Roskilde, Denmark
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 171
- Registration Number
- NCT05123703
- Locations
- 🇦🇷
Centro de Investigaciones Médicas Tucuman, San Miguel de Tucuman, Argentina
🇫🇷Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-bicêtre, France
🇮🇹Universita? G. D'Annunzio, Chieti, Abruzzo, Italy
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 109
- Registration Number
- NCT05119569
- Locations
- 🇺🇸
Fullerton Neurology and Headache Center, Fullerton, California, United States
🇺🇸Cleveland Clinic Lou Ruvo, Las Vegas, Nevada, United States
🇧🇦University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina